Evidence map›Paper›PMID 23532174›Full record

ArticleOchsner journal2013

Stimulators of soluble guanylyl cyclase: future clinical indications.

Bobby D Nossaman, Philip J Kadowitz

Open access · greenAbstract read
PubMed Full text at PMC
In one paragraph

Article in Ochsner journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Bobby D NossamanDepartment of Anesthesiology, Section of Critical Care Medicine, Ochsner Clinic Foundation, and ; The University of Queensland School of Medicine, Ochsner Clinical School, New Orleans, LA ; Department of Pharmacology, Tulane University School of Medicine, New Orleans, LA.
Philip J Kadowitz
Ochsner Medical Center · US

Funding

CARDIOPULMONARY SURGERY RESEARCHR01HL062000 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI KADOWITZ, PHILIP J · 2000 to 2008
$2.5M
Stem Cell Therapy for Pulmonary HypertensionR01HL077421 · NHLBI · TULANE UNIVERSITY OF LOUISIANA · PI KADOWITZ, PHILIP J · 2005 to 2008
$1.9M
NHLBI NIH HHS R01 HL062000NHLBI NIH HHS R01 HL077421
6 · The paper itself

Abstract

backgroundSoluble guanylyl cyclase (sGC) is expressed in mammalian cytoplasm and catalyzes the synthesis of the second messenger guanosine 3',5'-monophosphate (cGMP) involved in important physiological functions such as relaxation of vascular smooth muscle, inhibition of platelet aggregation, modulation of inflammation, and control of vascular permeability. sGC is the intracellular receptor for nitric oxide (NO) and the active moiety in traditional organic nitrate therapy, recently as an inhalant in the intensive care unit and experimentally in improving microcirculatory flow in shock. However, dysfunction of the heme moiety on sGC occurs in a number of cardiovascular diseases, which reduces NO effectiveness.

methodsIn this review, we examine animal studies and early clinical trials on agents that can directly stimulate sGC and may have future clinical application in cardiovascular disease and in perioperative care.

conclusionsAnimal and early clinical studies have shown that sGC stimulator agents have great promise for treating cardiopulmonary disorders and may also have a role in modulating the inflammatory response observed in perioperative care.

Indexed as

Cardiovascular diseasesdrug toleranceinflammationnitric oxidenitric oxide donorsnitroglycerinpulmonary hypertensionsoluble guanylyl cyclase

Identifiers

PMID23532174
PMCPMC3603178
OpenAlexW1873057643

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.